The US Food and Drug Administration approved Invega Sustenna extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults on Friday, July 31, 2009. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved in the US for this use.
SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS
Sign in with your MMM account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS
REGISTER FOR FREE WITH A MMM ACCOUNT
Enter your MMM registration email address to receive a new password.